New Neupogen Formula More Temperature Stable

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 5
Volume 6
Issue 5

THOUSAND OAKS, Calif--A new formulation of Neupogen (filgrastim or G-CSF) that contains sorbitol instead of mannitol is now available from Amgen.

THOUSAND OAKS, Calif--A new formulation of Neupogen (filgrastim or G-CSF)that contains sorbitol instead of mannitol is now available from Amgen.

The new formulation has the same clinical safety and efficacy profileas the mannitol-containing version, but offers additional flexibility withrespect to storage parameters.

Sorbitol-containing Neupogen will remain stable even if exposed to freezingtemperatures, as might occur in transit. The recommended storage temperaturewill continue to be 2° to 8° C. However, the gel tray insulationand freeze watch indicators required with mannitol-containing Neupogenwill be eliminated, allowing for smaller packaging and reduced need forrefrigerator inventory space.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content